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Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are hematological 
 disorders that occur at different stages of B-cell development. It has been shown that 
CLL B-cells can differentiate into plasma cells in vitro and in vivo. CLL is the most fre-
quent adult leukemia in the western world. It is a heterogeneous disease, characterized 
by clonal proliferation and the accumulation of mature CD5+ B lymphocytes (1). MM 
is a clonal plasma cell malignancy that accounts for more than 10% of all hematologic 
cancers (2). Although secondary cancers [particularly solid tumors (3–5)] can occur with 
CLL and MM, the concomitant occurrence of these two disorders in the same patient is 
rare [for a review of the few reported cases, see Ref. (6)]. The clonal relationship between 
these diseases has not always been clarified but is important in terms of understanding 
the pathogenesis and optimizing treatment. The clonal relationship between CLL and 
MM can be evaluated by (i) analyzing immunoglobulin (Ig) heavy chain and light chain 
(Ig kappa light chain and Ig lambda light chain) gene rearrangement, (ii) identifying and 
comparing somatic mutations, and (iii) studying chromosomic aberrations. Nevertheless, 
Ig rearrangements must always be interpreted in the light of specific phenomena such 
as allelic exclusion, B-cell receptor (BCR) revision (VH and DH gene replacement), BCR 
editing, and somatic mutations—events that were not considered in previous studies. 
These issues can be addressed by sequencing the rearranged Ig genes from sorted 
populations and interpreting the generated data. In the present study, we evaluated the 
putative clonal relationship between the two diseases by combining DNA copy number 
Abbreviations: BCR, B-cell receptor; BMMC, bone marrow mononuclear cell; CDR3, complementarity-determining region 
3; CGH, comparative genomic hybridization; CLL, chronic lymphocytic leukemia; FACS, fluorescence-activated cell sorting; 
HSC, hematopoietic stem cell; IGH, immunoglobulin heavy chain; IGK, immunoglobulin kappa light chain; IGL, Ig lambda 
locus; MM, multiple myeloma; PBMC, peripheral blood mononuclear cell; RSS, recombination signal sequence.
2Trudel et al. Biclonal Origin in Concomitant CLL and MM
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 625
analysis with an assessment of Ig gene rearrangements [clonality assessment, V(D)J 
sequencing, and somatic hypermutation analysis] in highly enriched CD19+ CD5+ (CLL) 
and CD38+ CD138+ (MM) cell populations. Array comparative genomic hybridization 
data suggested a possible phylogenic progression from CLL to MM. Moreover, V(D)J 
sequencing indicated that both CLL and MM cells used the same VH and JH genes but 
different DH genes. However, in-depth analysis and interpretation of Ig gene rearrange-
ments ultimately suggested that the two diseases had distinct clonal origins.
Keywords: concomitant hematological malignancies, clonal origin, immunoglobulin gene rearrangement, DNa 
copy number, cell sorting
Case pReseNtatIoN
In 2004, a 75-year-old woman was referred to our institution 
for monoclonal gammopathy. Laboratory screening revealed 
elevated serum levels of monoclonal IgG (20  g/l) and κ light 
chains (300 mg/l) in the absence of anemia and kidney failure. 
X-rays did not show any osteolytic lesions. A bone marrow biopsy 
revealed that 10% of the plasma cells were atypical. These results 
supported a diagnosis of Durie–Salmon stage I, International 
Staging System stage 1 IgG kappa multiple myeloma (MM). From 
2004 to 2009, the patient did not present with an indication for 
treatment and so underwent regular clinical follow-up and labo-
ratory tests. In October 2009, a complete blood count revealed an 
increase in the lymphocyte count (5.109/l). Using flow cytometric 
immunophenotyping, the peripheral lymphocytes were positive 
for CD5, CD20, and CD23 (with expression of IgM and IgD 
lambda) and negative for CD38; this profile was consistent with a 
diagnosis of chronic lymphocytic leukemia (CLL; Matutes score: 
5). A second bone marrow biopsy revealed major infiltration 
(59%) by atypical plasma cells and the presence of small, mature-
looking lymphocytes with the same immunophenotype as 
peripheral lymphocytes. At this time, the patient did not present 
with lymphadenopathy, hepatosplenomegaly, or marked anemia 
and thrombopenia. We therefore diagnosed Binet stage A CLL 
in a patient with previously diagnosed MM. Given the lack of 
symptoms and the early disease stage, the patient did not require 
immediate treatment for CLL. Nevertheless, following an increase 
in the serum-free kappa light chain concentration (1000  mg/l) 
and the observation of rib fractures on chest X-rays, we decided 
to treat the patient with bortezomib–melphalan–prednisone. 
Meanwhile, the patient gave his written informed consent to 
performance of the molecular analyses and to publication of the 
present report.
MateRIaLs aND MetHoDs
Cell Isolation
Samples of peripheral blood and bone marrow were obtained 
(before treatment) from the patient. Peripheral blood mono-
nuclear cells (PBMCs) and bone marrow mononuclear cells 
(BMMCs) were isolated using Ficoll-Hypaque™ density gradient 
centrifugation. CD19+ CD5+ CLL cells and CD38+ CD138+ 
MM cells were sorted using fluorescence-activated cell sorting 
(FACS) (Ariall, BD Biosciences). Genomic DNA was isolated 
from each sorted population using a DNeasy kit (Qiagen) and 
was employed in all subsequent molecular analyses.
Clonality assessment, V(D)J sequencing, 
and somatic Hypermutation analysis
Genomic DNA samples from the cell-sorted populations under-
went an immunoglobulin (Ig) heavy chain (IGH) and light chain 
[Ig kappa light chain (IGK) and Ig lambda light chain] gene rear-
rangement analysis using multiplex PCR and the standardized 
BIOMED-II Concerted Action protocol (7).
For the clonality assessment with fragment analysis, 1  µl of 
PCR product was mixed with 0.5 µl of a dye-labeled size standard 
[GeneScan™ 500 LIZ™ dye size standard (Applied Biosystems)] 
and 12  µl of deionized formamide (Hi-Di™ Formamide, Life 
Technologies), and denatured for 1 min at 95°C. Subsequently, 
fluorescent PCR products were separated by capillary electropho-
resis on a 3500xL Dx Genetic Analyzer (Applied Biosystems) and 
sized using GeneMapper® Software v4.1.
For the analysis of V, D, and J sequences, approximately 
5  µl of purified PCR product were sequenced using BigDye® 
Terminator v1.1 Cycle Sequencing Kit, according to the manu-
facturer’s instructions (Applied Biosystems). Electropherograms 
were analyzed with Sequencing Analysis v.3.7 software (Applied 
Biosystems), and sequence data were interpreted using the 
IMGT® database1 (8) and the Basic Local Alignment Search 
Tool. The mutation frequency was calculated as the percentage 
of mutations per VH sequence after the detection of mutations in 
both strands (sense and antisense).
DNa Copy Number analysis
Array comparative genomic hybridization experiments were 
performed in accordance with the manufacturer’s instructions 
(Agilent). Briefly, 500  ng of DNA were digested with Rsa/Alu, 
labeled with either Cy3-dCTP or Cy5-dCTP, and competitively 
hybridized with human reference genomic DNA (female) on 
4 ×  44  k comparative genomic hybridization (CGH) microar-
rays. The arrays were washed and scanned, and the images were 
extracted using Feature Extraction software. Data were analyzed 
with Cytogenomics software version 2.7.
1 http://www.imgt.org.
FIGuRe 1 | Cell sorting of CD19+ CD5+ pBMCs (upper panel) and CD38+ CD138+ BMMCs (lower panel). Figures show the total cell population (a) and 
the percentage of the cell populations stained with anti-CD19 and anti-CD5 or anti-CD38 and anti-CD138 before sorting (B) and after sorting (C).
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ResuLts aND DIsCussIoN
Plasma cells are terminally differentiated B cells. It has been 
shown that CLL B-cells can differentiate spontaneously into 
antibody-secreting plasma cells in vivo (9, 10) and in vitro, when 
exposed to various stimuli and can produce IgM, IgG, and IgA 
(11, 12). It is thus possible that the malignant plasma cells are 
differentiated or transformed CLL B-cells (hypothesis 1, H1). The 
two malignancies may also arise independently from the same 
premalignant hematopoietic stem cell (HSC) (hypothesis 2, H2) 
or from an early-stage differentiated B-cell (hypothesis 3, H3).
Our phenotyping data revealed that the CLL B-cells and 
malignant plasma cells expressed different Ig heavy and light 
chain isotypes (IgM and IgD lambda for the CLL B-cells, and IgG 
kappa for the malignant plasma cells), which suggested a different 
clonal origin. However, it has been shown that different Ig heavy 
and light chain phenotypes can arise from identical primary 
rearrangements and thus may correspond to a common clonal 
origin (13).
To establish whether MM cells are differentiated or transformed 
CLL B-cells (H1) or whether CLL and MM arose independently 
from the same premalignant HSC (H2) or from an early B-cell 
progenitor that had not begun to rearrange its Ig genes (H3), we 
decided to analyze the copy number variation (using array CGH) 
after cell sorting. Cytogenetic aberrations (such as deletions, loss 
of heterozygosity, duplications, or translocations) can drive car-
cinogenesis and cause clonal evolution, which is associated with 
disease progression and a poor clinical prognosis. Cytogenetic 
aberrations in HSCs occur in a number of hematological cancers, 
including CLL (14–16) and MM (17, 18). Indeed, the HSC’s 
genetic heritage is transmitted to the progeny; if this stem cell 
carries chromosomal aberrations that can be detected by array 
CGH, they should be present in the CLL and MM populations.
After isolating PBMCs and BMMCs, we used FACS to obtain 
highly enriched CD19+ CD5+ (CLL) and CD38+ CD138+ 
(MM) cell populations (purity: 99.4 and 99.7%, respectively), as 
shown in Figure 1. A DNA copy number analysis revealed both 
amplifications (gain 1q21.1-q44, 104.1  Mb) and deletions (del 
X, 145.7 Mb) in CD38+ CD138+ sorted cells, whereas no aber-
rations were detected in CD19+ CD5+ sorted cells (Figure 2). 
The absence of common genomic aberrations in the two cell 
populations argues against the involvement of an early B-cell 
progenitor (H2). However, the detection of genetic aberrations 
in CD38+ CD138+ selected cells suggests that the malignant 
plasma cells were differentiated or transformed CLL B-cells (H1). 
This hypothesis can be evaluated by analyzing Ig heavy and light 
chain gene rearrangements.
During early B-cell differentiation in the bone marrow, IGH 
gene rearrangement precedes Ig light chain gene rearrangement. 
The DH to JH rearrangement occurs at the pro-B cell stage and pro-
duces an incomplete DJH rearrangement. This is followed by VH to 
DJH rearrangement at the pre-B cell stage, which is thought to give 
rise to a complete, functional VDJ rearrangement. Following suc-
cessful IGH recombination, the Ig light chain loci then rearrange 
FIGuRe 2 | DNa copy number analysis. The genome view (upper panel) generated from array comparative genomic hybridization data did not show any 
detectable aberrations in DNA extracted from CD19+ CD5+ selected cells but revealed amplification/deletion events in DNA extracted from CD38+ CD138+ 
selected cells. A comparison of chromosome views (lower panel) shows a gain of the long arm of chromosome 1 (1q) (with a log ratio of +0.3) and a loss of 
chromosome X (with a log ratio of −0.3) in DNA extracted from CD38+ CD138+ selected cells.
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themselves. After initial attempts occur at the Ig kappa locus 
(IGK); if a non-functional IgK or self-reactive rearrangement is 
achieved, the Ig lambda locus (IGL) then undergoes rearrange-
ment. If VDJH and VJL are functional, the cell will develop into a 
mature naïve B-cell that co-express surface IgM/IgD; otherwise, 
the cell will undergo apoptosis or become anergic. When mature 
B-cells are activated by an antigen, they enter the germinal 
center, where somatic mutations and class-switch recombination 
occur. The B-cell goes through safety checkpoints at different 
stages of differentiation, and it may undergo additional rounds 
FIGuRe 3 | Clonality assessment and V(D)J sequencing. Electropherograms reveal different monoclonal peaks in the Ig heavy chain (upper panel) and Ig light 
chain kappa (lower panel) framework regions in CD19+ CD5+ PBMCs and in CD38+ CD138+ BMMCs. The sequence of each V(D)J rearrangement is indicated on 
the corresponding electropherogram.
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of rearrangement before (editing) or after (revision) it leaves the 
bone marrow (19, 20). As a result of the stepwise Ig gene rear-
rangement and accumulation of somatic V gene mutations, an 
analysis of the rearranged Ig genes in concomitant B-cell cancers 
provides information about the clonal relationship and the pro-
genitor cell’s differentiation stage. Accordingly, two B-cells with 
the same IgH rearrangements but different IgL types may have a 
common clonal origin (13). In contrast, B-cells with different IgH 
rearrangements will always initially be considered to be biclonal.
We therefore studied IGH and light chain (IGK, IGL) gene 
rearrangements by analyzing genomic DNA from the cell-sorted 
populations. Assessment of the IGH locus identified monoclonal 
peaks in CD19+ CD5+ selected cells and in CD38+ CD138+ 
selected cells in multiplex VHFR1–JH, VHFR2–JH, and VHFR3–JH 
PCRs (Figure  3, upper panel VHFR1–JH, data not shown for 
VHFR2–JH and VHFR3–JH). A monoclonal peak was also detected 
using a multiplex DH–JH PCR in the CD19+ CD5+ cell popula-
tion. Analysis of the IGK locus using multiplex VK–JK and VK/
intron-Kde PCRs showed four monoclonal peaks in CD19+ 
CD5+ cells and two completely different peaks for CD38+ 
CD138+ (Figure  3, lower panel). Sequence analysis suggested 
that the PCR product with a peak size of 150 nt was a shorter 
amplification product of the peak at 288 nt. Multiplex PCR for 
the IGL locus displayed polyclonal Gaussian profiles for both 
populations (data not shown).
Sequencing of VHFR1–JH PCR products from the CD19+ 
CD5+ and CD38+ CD138+ fractions revealed identical VH 
(IGHV4-59*01) and JH (IGHJ4*02) gene usage in both CLL and 
MM but different DH gene usage (IGHD2-2*01 for CLL and 
IGHD1-26*01 for MM). In this context, one can imagine that 
a DH-replacement mechanism in a CLL B-cell gave rise to the 
V(D)J combination observed in the MM. D-replacement is a 
RAG-mediated, secondary recombination process that relies on 
the recognition of cryptic recombination signal sequences (RSSs) 
in the VH element. It results in changes to the junction nucleotide 
sequences (21). We therefore analyzed the VH-3′region of each 
rearrangement and found that the cryptic RSSs and the surround-
ing region were conserved. These results strongly suggest (i) DH 
replacement did not occur in this particular case and (ii) the 
two V(D)J rearrangements originated from independent clones 
(despite the same VH and JH gene usage). Moreover, the incomplete 
IGHD2-2/IGHJ6 rearrangement identified in CD19+ CD5+ 
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cells could not have served as a basis for the complete IGHV4-
59*01/IGHD1-26*01/IGHJ4*02 rearrangement observed in the 
MM; IGHJ6 is the most distal JH gene in the IGH locus, and the 
IGHD2-2/IGHJ6 recombination process led to the deletion of all 
JH genes2 (IGHJ1 to IGHJ5).
Chronic lymphocytic leukemia is believed to be driven by 
antigen–B-cell receptor (BCR) interactions (22). In this regard, 
studies have identified specific target such as bacterial antigen as 
well as auto-antigens that interact with CLL BCR. This notion is 
supported by the identification of closely homologous antigen 
binding sites between unrelated cases called stereotyped BCR 
(23). Stereotyped BCR uses a specific IGHV/IGHD/IGHJ genes 
rearrangement with nearly identical heavy and light chain 
complementarity-determining region 3 (CDR3) sequences and 
so identical antibody motifs. Up to one-third of patients with 
CLL have stereotyped BCR (23, 24). In this report, the usage of 
identical VH and JH genes was found in both CLL and MM. The 
sharing of motif that recognizes a same antigen may have driven 
the development of the two malignancies from independent 
B cell clones. However, the comparison of CDR3 length and the 
corresponding amino acid in CLL and MM, showed a higher 
CDR3 length in CLL and a different amino acid sequence, 
because of a different DH gene usage and the higher N diversity 
in DJ junction.
There are few literature reports of light chain gene rear-
rangement before heavy chain rearrangement (25). Therefore, 
we also considered the possible phylogeny of light chain rear-
rangements. Sequencing of both the rearrangements involving 
the Kde segment—one with the cryptic intron RSS and the 
removal of 16 nucleotides (in CLL) and the other with the 
IGKV1-17 gene and the deletion of one nucleotide (in MM)—
confirmed the absence of common recombination events. Two 
VKJK rearrangement configurations are possible in CLL, since 
recombination of IGKV4-1 segment occurs by inversion: the 
two VKJK rearrangements can be located on the same haplotype 
or on different ones. If VKJK rearrangements are located on the 
same haplotype, the IGKV4-1/IGKJ5 rearrangement necessarily 
preceded the IGKV2-29/IGKJ1 rearrangement; the latter would 
also have occurred by inversion in this new configuration. The 
IGKV1-5 and IGKJ2 genes are maintained on this haplotype and 
are thus available for subsequent rearrangement (via deletion) 
in MM. When considering possible phylogenies, the two CLL 
rearrangements would still be present in MM cells. However, 
IGKV1-5/IGKJ2 was the only rearrangement detected in CD38+ 
CD138+ cells—thus ruling out a common origin. However, if 
VKJK rearrangements are located on different haplotypes (given 
that the IGKV2-29/IGKJ1 rearrangement deletes the IGKV1-5 
segment), the IGKV1-5/JK2 rearrangement would be located 
on the haplotype bearing the IGKV4-1/IGKJ5 rearrangement. 
When considering possible phylogenies, the two CLL rearrange-
ments would again still be present in MM cells, which is not what 
we observed.
Surprisingly, phenotyping data revealed a lambda monotype 
for CLL cells, whereas multiplex PCRs for the IGL locus displayed 
2 http://www.imgt.org/IMGTrepertoire/LocusGenes/#B.
a polyclonal Gaussian profile in the two populations (data not 
shown). The high mutation frequency (>9%) observed for Ig 
gene rearrangements in the CLL B-cell population might explain 
why the clonal rearrangement was not amplified (i.e., no primer 
hybridization) and why the observed Gaussian profile could 
have come from polyclonal CD19+ CD5+ non-CLL B-cells. 
This discrepancy was partially resolved when sequencing studies 
revealed that IGKV2-29/IGKJ1 is an unproductive, rearranged 
IGK sequence (with a stop codon in CDR3 IGKV2-29). Even 
though the IGKV4-1/IGKJ5 rearrangement generated an open 
reading frame, the absence of kappa light chain production was 
certainly caused by the deletion of the kappa constant segment by 
the observed intron-Kde rearrangement.
In summary, our array CGH results in a highly purified cell 
population revealed that CLL cells did not have any detectable 
aberrations, whereas MM cells presented chromosome loss 
and gain. This prompted us to consider a possible phylogenic 
evolution from CLL to MM. In this particular context, only an 
in-depth analysis of Ig gene rearrangements could unambigu-
ously determine the nature of the clonal relationship. A frag-
ment analysis first revealed that the monoclonal components in 
CLL and MM differed in size. Nevertheless, when considering 
possible secondary recombination events (revision, editing, 
and replacement), this discrepancy did not rule out a primary 
common recombination event. This possibility was supported 
when IGH sequencing showed identical VH and JH gene usage 
in both CLL and MM cells. However, the observed DH gene 
alignment and the lack of detectable secondary recombination 
events ruled out a transformation from CLL to MM (H1). 
Furthermore, it is unlikely that an early differentiated B-cell 
was a progenitor of both malignancies (H3) because common 
molecular stigmata would have been seen. Given the absence 
of a clonal relationship between CLL and MM, the most likely 
hypothesis (H2) involves the existence of a premalignant HSC 
(although our present data cannot prove this and cannot 
exclude the possibility that the two malignancies derived from 
independent HSC).
In patients with concomitant hematological diseases, the pres-
ence or absence of a clonal relationship can be formally addressed 
by combining an in-depth analysis of Ig gene rearrangements 
with a DNA copy number analysis in a highly purified, cell-sorted 
population.
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